|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
|
| Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
|
| Affiliations(s): "1
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
2
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
3
Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea
4
Kansai Electric Power Medical Research Institute, Kobe, Japan
5
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
6
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
7
Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
8
Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan
9
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan
10
Department of Cardiovascular Medicine, Saga University, Saga, Japan
11
Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan
12
Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan
13
Boehringer Ingelheim Korea Ltd, Seoul, Korea
14
IQVIA, Espoo, Finland
15
Boehringer Ingelheim International GmbH, Ingelheim, Germany
16
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
17
Kansai Electric Power Hospital, Osaka, Japan
" |
Publication(s): "JDI journal
Virtual Conference: ACC, May 2021"
|
| Document Type(s): Article, |
| Countries: Japan, Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis, |
|
|
| |
| |
| Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: a real-world data analysis |
| Author(s): Hirokazu Takahashi 1 2, Keiko Asakawa 3, Yoshinori Kosakai 3, Takumi Lee 3, Mitsuhiro Rokuda 3 (rwesheorj A) |
| Affiliations(s): 1) Liver Center, Saga University Hospital, Saga, Japan
2) Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
3) Astellas Pharma Inc., Tokyo, Japan |
Publication(s): Diabetes Obesity and Metabolism
|
| Document Type(s): Article, Online article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2023 |
|
L:
A: |
English
Database Study, Retrospective cohort analysis, |
|
|
| |
| |
| Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
|
| Author(s): "Kerstin M G Brand, Laura Saarelainen, Jaak Sonajalg, Emmanuelle Boutmy, Caroline Foch, Marja Vääräsmäki, Laure Morin-Papunen, Judith Schlachter, CLUE Study Group, Katja M Hakkarainen, Pasi Korhonen
CLUE Study Group: Minna Vehkala, Robyn Thorén, Henrik Svanström "
|
| Affiliations(s): "Leading author: Kerstin Brand: Merck KGaA, Darmstadt, Germany
IQVIA author affiliations: Global Database Studies, IQVIA, Espoo, Finland; Global Database Studies, IQVIA, Tartu, Estonia; Global Database Studies, IQVIA, Solna, Sweden; Global Database Studies, IQVIA"
|
Publication(s): BMJ Open Diab Res Care 2022;10:e002363. doi:10.1136/bmjdrc-2021-002363
|
| Document Type(s): Article, |
| Countries: Finland, |
| Click here for the abstract |
C:
Y: |
Diabetes, Obesity,
2022 |
|
L:
A: |
English
Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective cohort analysis, |
|
|
| |
| |
| Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study
|
| Author(s): Kerstin MG Brand1, Robyn Thoren2, Jaak Sõnajalg3, Emmanuelle Boutmy1, http://orcid.org/0000-0002-0254-5560Caroline Foch1, Judith Schlachter1, Katja M Hakkarainen2, Laura Saarelainen4 |
| Affiliations(s): Merck KGaA, Darmstadt, Germany
Global Database Studies, IQVIA, Solna, Sweden
Global Database Studies, IQVIA, Tartu, Estonia
Global Database Studies, IQVIA, Espoo, Finland |
Publication(s): BMJ Open Diab Res Care 2022;10:e003056. doi:10.1136/bmjdrc-2022-003056
|
| Document Type(s): Article, |
| Countries: Finland, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2022 |
|
L:
A: |
English
Observational study, Population Based Study, |
|
|
| |
| |
| High‑Expenditure Disease in the EU‑28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? |
| Author(s): Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck |
| Affiliations(s): Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium |
Publication(s): PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4
|
| Document Type(s): Article, |
| Countries: Europe, |
| Click here for the abstract |
C:
Y: |
Diabetes, Health economics, Oncology,
2021 |
|
L:
A: |
English
Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review, |
|
|
| |
| |
| The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease |
| Author(s): Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7 |
| Affiliations(s): 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
2IQVIA Real World Solutions, Zaventem, Belgium.
3IQVIA Real World Solutions, London, UK.
4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark.
5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk.
6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk.
7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. |
Publication(s): Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y
IQVIA HEOR Zaventem Brussels
PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y
|
| Document Type(s): |
| Countries: Denmark, |
| Click here for the abstract |
C:
Y: |
Diabetes, Health economics,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China |
| Author(s): Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7 |
| Affiliations(s): 1IQVIA, Real World Solutions, Zaventem 1930, Belgium.
2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China.
4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal.
5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China.
6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany.
7IQVIA, Global HEOR, Zaventem 1930, Belgium. |
Publication(s): Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284.
PMID: 33576249 DOI: 10.2217/cer-2020-0284
|
| Document Type(s): Article, |
| Countries: China, |
| Click here for the abstract |
C:
Y: |
Diabetes, Health economics,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies |
| Author(s): Jonathan Pearson-Stuttard 1, Nikos Papadimitriou 2 3, Georgios Markozannes 2, Sofia Cividini 4, Artemisia Kakourou 2, Dipender Gill 5, Evangelos C Rizos 6 7, Grace Monori 5, Heather A Ward 5, Maria Kyrgiou 8 9, Marc J Gunter 3, Konstantinos K Tsilidis 2 5
|
| Affiliations(s): 1Department of Epidemiology and Biostatistics, MRC-PHE Center for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. j.pearson-stuttard@imperial.ac.uk.
2Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
3Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.
4Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom.
5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
6Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece.
7School of Medicine, European University of Cyprus, Nicosia, Cyprus.
8Department of Gut, Metabolism and Reproduction, and Surgery and Cancer, IRDB, Imperial College London, London, United Kingdom.
9West London Gynecological Cancer Center, Imperial NHS Trust, London, United Kingdom.
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
IQVIA. |
Publication(s): PMID: 33737302 DOI: 10.1158/1055-9965.EPI-20-1245
|
| Document Type(s): Article, |
| Countries: |
| Click here for the abstract |
C:
Y: |
Diabetes,
2021 |
|
L:
A: |
English
Epidemiological study, Literature Review, Meta analysis, |
|
|
| |
| |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from
the empagliflozin comparative effectiveness and safety (EMPRISE) study
|
| Author(s): A. Karasik1
, S. Lanzinger2
, E. Chia-Hui Tan3
, D. Yabe4
, D. Jung Kim5
, W. H-H Sheu6
, C. MelzerCohen1
, R.W. Holl2
, K. Ha5
, T. Nyström7
, L. Niskanen8
, M. Linnemann Jensen9
, M.H. Kyaw10, J.
Núñez11, EMPRISE EU and East Asia Study Group; |
| Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2
Inst. for
Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese
Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of
Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine,
Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical
Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine,
Päijät-Häme Central Hospital, Lahti, Finland, 9
IQVIA, Copenhagen, Denmark, 10Boehringer
Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico
Universitario de Valencia, Valencia, Spain |
Publication(s):
https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Population Based Study, |
|
|
| |
| |
 1 of 62 
|
|
